Coherus BioSciences focuses on biosimilars as investors watch Nasdaq listing

By Christina Vaughn, Background & Management desk. Reviewed on July 7, 2026 at 8:06 a.m. ET.

Coherus BioSciences (ISIN US19247A1007) is a biopharmaceutical company listed on Nasdaq that concentrates on biosimilar and immuno-oncology products. The group aims to compete with established branded therapies by offering lower-cost alternatives and selected innovative treatments, a positioning that can appeal to cost-conscious healthcare systems and investors looking at long-term demand for biologic medicines.

Biosimilar-focused business strategy

The company’s core strategy centers on developing and commercializing biosimilar versions of major biologic drugs used in areas such as oncology, immunology and ophthalmology. Biosimilars are highly similar to already approved biologic medicines, with no clinically meaningful differences in safety or effectiveness, but they can typically be offered at a discount to originator brands after patent protection expires. This model is designed to benefit payers and patients while providing Coherus BioSciences with a portfolio tied to proven mechanisms of action.

To build that portfolio, the company invests in clinical development, regulatory submissions and commercial infrastructure in key markets. The work includes conducting comparative clinical studies against reference products, gathering safety data and responding to questions from regulators. Once a biosimilar gains approval, the commercial effort shifts to building relationships with healthcare providers, specialty pharmacies and hospital systems that decide which medicines are placed on formularies. Over time, the goal is to expand indications and geographic reach, turning each asset into a longer-lived revenue contributor.

Immuno-oncology additions complement biosimilars

Beyond biosimilars, Coherus BioSciences pursues selected immuno-oncology assets that could provide upside if they deliver differentiating clinical results. Immuno-oncology therapies aim to harness the body’s immune system to fight cancer, using mechanisms such as checkpoint inhibition or modulation of immune cell activity. By combining these programs with the biosimilar platform, the company seeks a mix of nearer-term biosimilar cash flows and longer-term potential from innovative cancer treatments.

This blend of established biology and innovation can influence how analysts view the company’s risk profile. Biosimilars are generally seen as lower-risk than first-in-class drugs because they rely on proven targets and known safety profiles, although competition and pricing pressure can be intense. Innovative oncology programs, on the other hand, usually carry higher scientific and clinical risk but may support stronger margins or differentiated positioning if trials succeed. For investors, understanding this balance between biosimilar volume and possible upside from oncology is central to assessing the business.

Representative biosimilar product

One representative biosimilar concept for Coherus BioSciences is a monoclonal antibody designed to mirror the action of a reference biologic used in cancer treatment. Such a product would undergo comparative analytical testing, pharmacokinetic studies and at least one clinical trial in a key indication to demonstrate similarity in efficacy and safety. After securing regulatory approval, the medicine would be marketed for use in hospitals and infusion centers where oncologists treat patients with the originator drug. Pricing strategies for this type of biosimilar typically aim to undercut the branded medicine while still supporting investment in manufacturing and quality control.

Stock listing and trading venue

Coherus BioSciences is listed on Nasdaq in the United States, giving investors access to its shares through a major US exchange. Nasdaq is known for hosting many technology and healthcare companies, and membership offers visibility with institutional and retail investors who follow the broader index and sector benchmarks. The share price reflects expectations around biosimilar uptake, competitive dynamics against other producers, and progress in immuno-oncology programs, although exact intraday levels can change frequently during regular trading hours.

This article was generated automatically and technically reviewed before publication. Market prices, analyst data and company information are provided without warranty and may change at short notice. This content is for informational purposes only and is not investment, financial, legal or tax advice. It is not a recommendation to buy or sell any security. Investing in securities involves risk, including the possible loss of principal.